Monopar Initiated Drug Submission for Wilson Disease
The application for ALXN1840 marks a step toward a new treatment option for those living with this rare genetic disorder.
Updated on Sept. 23, 2026 in Diseases — General
Live Poll
Do you believe pharmaceutical companies are doing enough to develop new treatments for rare diseases?
On July 22, 2026, Monopar Therapeutics began a rolling submission of a New Drug Application (NDA) to the FDA for ALXN1840. The drug is currently being evaluated as a potential therapy for patients with Wilson disease.
Why it matters
Wilson disease is a rare genetic condition that prevents the body from properly excreting copper, resulting in toxic buildup that can damage vital organs. A new treatment with a novel mechanism of action could offer a long-awaited alternative to existing options for the affected population.
In a Phase 3 trial, ALXN1840 met its primary endpoint over a 48-week duration. The clinical program included 645 patient-years of follow-up among 266 participants.
The players
Monopar Therapeutics
A Wilmette, Illinois-based biopharmaceutical company focused on developing therapies for orphan diseases.
FDA
The federal agency responsible for regulating the safety and efficacy of pharmaceutical products in the United States.
The details
Wilson disease is caused by mutations in the ATP7B gene, which impairs copper excretion. ALXN1840 works by mobilizing and sequestering this excess copper in albumin tripartite complexes, preventing the mineral from reaching toxic levels in the body. The rolling NDA process allows the company to submit completed sections of the application to the FDA while finalizing the remaining technical data.
Timeline
June 2026: ALXN1840 received Rare Pediatric Disease designation from the FDA.
July 22, 2026: Monopar Therapeutics initiated the rolling NDA submission process.
Health Landscape
The pursuit of ALXN1840 aligns with the FDA Rare Pediatric Disease designation program, which encourages the development of new therapies for niche conditions. If approved, this drug would represent the first treatment with this specific mechanism of action for Wilson disease in several decades.
Wilson disease affects approximately 1 in 30,000 people worldwide and requires careful clinical management to prevent toxic copper accumulation. Patients should speak with their physician about current treatment standards and monitor emerging data regarding new drug developments.
The takeaway
The initiation of an NDA submission for ALXN1840 highlights ongoing efforts to find new ways to treat copper accumulation in Wilson disease. Individuals with the condition should continue to work closely with their medical team to track their copper levels and discuss the latest developments in care.
Further reading
For more information on managing rare genetic conditions, visit the Diseases — General section.
Source note: This article includes information reported by Drugs.
Live Poll
Do you believe pharmaceutical companies are doing enough to develop new treatments for rare diseases?
